KEYSTONE 420

08/15/2026

Pa. patients swear by cannabis as a tool to fight opioid addiction.
https://www.inquirer.com/health/opioid-addiction/spl/pa-opioid-addiction-medical-ma*****na-research-20210805.html?fbclid=IwAR1YpQHErDcZx9y6DCH3Th08xlmLPdhOSU_8u5QMrHwAEUbpqIRr4c3MZJQ

Pennsylvania approved opioid use disorder as a condition that qualifies a person for medical ma*****na in 2018, but experts are still conflicted about its use as an addiction treatment.

08/15/2026

The administration of a proprietary, water-soluble CBD tablet mitigates neuropathic foot pain compared to placebo, according to randomized clinical trial data published in the Journal of Diabetes & Metabolism.

Researchers affiliated with Pure Green Pharmaceuticals assessed the efficacy of sublingual CBD tablets (20mg) versus placebo in a cohort of subjects with painful diabetic peripheral neuropathy (pDPN) pain in their feet. Subjects were administered either the active drug or a placebo three times per day for 28 days.

Those taking the active drug reported significant reductions in pain compared to placebo and no adverse side-effects. Subjects taking CBD also reported improvements in their sleep quality and reduced levels of anxiety.

Authors concluded: “This 28-day trial revealed statistically and clinically significant improvement in pain and a clinically significant improvement in sleep quality and in anxiety reduction for those in the CBD treatment group. Additionally, subjects taking CBD affirmed these results by having a statistically significant greater response to treatment as compared with subjects taking placebo. The benefit of this study demonstrates that the sublingual 20 mg CBD tablet should be considered as a safe and effective treatment for pDPN.”

Numerous placebo-controlled clinical trials similarly document the ability of whole-plant cannabis to mitigate neuropathic pain in a wide range of patient populations, including in subjects with HIV and diabetes.

Full text of the study, “Cannabidiol for the treatment of painful diabetic peripheral neuropathy of the feet: A placebo-controlled, double-blind, randomized trial,” appears in the Journal of Diabetes & Metabolism. Additional information on cannabinoids and neuropathy is available from NORML.

https://norml.org/news/2021/08/05/clinical-trial-sublingual-administration-of-cbd-is-effective-in-patients-with-diabetic-neuropathy/?fbclid=IwAR3dhSe87tr14P3ms-YERIAwpavlVkOEOJeax0LmQoWfifO7hOtgmrzt3F4

Authors reported, "This study demonstrates that the sublingual 20 mg CBD tablet should be considered as a safe and effective treatment for pDPN."

08/11/2026

A combination of THC and CBD significantly reduced agitation in people with late-stage dementia “These trial results were extremely impressive and showed a level of response not seen before in clinical trials related to dementia,” he said. “Rarely do we see close to 90 percent of patients in a trial respond positively to a new medication.”

https://www.eurekalert.org/news-releases/1135740

In a first-of-its-kind clinical trial, U.S. researchers have found that people with agitation and dementia in late life who took a special medical formulation of two active ingredients found in ma*****na – THC and CBD – had significantly less agitation compared to people who received a p...

07/10/2026

NEVER FORGET! The DEA, a government agency, was behind submitting false propaganda in court to criminalize cannabis in collaboration with the multi-millionaire media mogul William Randolph Hearst (Patty Hearst was his granddaughter).

New data is now available on the effectiveness of cannabinoids, a cannabis extract, for the treatment of patients with severe forms of drug-resistant epilepsy.

07/03/2026

Happy INDEPENDENCE Day KEYSTONERS!

06/27/2026

06/19/2026

Happy Father's Day KEYSTONERS!